Document is current

Article History

Received: 2 April 2022

Accepted: 28 June 2022

First Online: 6 July 2022

Declarations

:

: The endocannabinoid system has a neuro-modulatory role that influences many physiological functions, including pain processing and modulation of trigeminal excitability, pathophysiological assumption supporting the possible usefulness in the treatment of migraine. As found in a recent review [], the growing body of supporting evidence consists of retrospective studies, online surveys, case series, and case reports, and migraine patients enrolled in these studies usually used different cannabis preparations through different routes of administration, making it difficult to explore the therapeutic potential of the Cannabis plant. Proper placebo-controlled trials are needed to establish the therapeutic role for cannabinoids (plant-derived or synthetic) in migraine treatment.Ethical approval.This article does not contain any study with human subjects performed by any of the authors.

: The authors declare no competing interests.